Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 10/20 | 0.55 |
| ▸ | GRM5 | P41594 | 9/20 | 0.55 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | ATR | Q13535 | 2/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675208 | 1.00 | GRM1 (0.55) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL15168000 | 0.90 | TNK2 (0.50) | GRM1GRM5TNK2CYP11B2ATR | |
| SCHEMBL22328950 | 0.89 | GRM1 (0.57) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL31583898 | 0.87 | GRM1 (0.55) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL23705785 | 0.86 | GRM5 (0.57) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL1463273 | 0.85 | GRM1 (0.51) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL27167796 | 0.83 | GRM1 (0.52) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL31700785 | 0.83 | GRM1 (0.52) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL29976826 | 0.83 | GRM1 (0.52) | GRM1GRM5TNK2CYP11B2CDK9 | |
| SCHEMBL6396667 | 0.83 | PDK4 (0.52) | GRM1GRM5TNK2CYP11B2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3728252-B1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3728252-B1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-27 | — | — | US | disclosed |
| US-11053244-B1 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053244-B1 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-10730877-B2 | 4-Azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-10730877-B2 | 4-Azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-26 | — | — | US | disclosed |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-26 | — | — | US | disclosed |
| US-10544143-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544143-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | SYNGENE INTERNATIONAL LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | SYNGENE INTERNATIONAL LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | GRM1 117/4885GRM5 58/4885TNK2 448/4885 |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | GRM1 117/4885GRM5 58/4885TNK2 448/4885 |
| US-11053244-B1 | 4-azaindole compounds | TLR7, TLR9, TLR5 | GRM1 117/4885GRM5 58/4885TNK2 448/4885 |
| US-10544143-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | GRM1 117/4885GRM5 58/4885TNK2 448/4885 |
| US-10730877-B2 | 4-Azaindole compounds | TLR7, TLR9, TLR5 | GRM1 117/4885GRM5 58/4885TNK2 448/4885 |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | GRM1 117/4885GRM5 58/4885TNK2 448/4885 |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | GRM1 117/4885GRM5 58/4885TNK2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.